The WSJ on Doha Declaration on TRIPS and Public Health, in 2001
This was the Wall Street Journal’s take on the Doha Declaration on TRIPS and Public Health, two days after the agreement was reached:
This was the Wall Street Journal’s take on the Doha Declaration on TRIPS and Public Health, two days after the agreement was reached:
CONTACT:
Zack Struver
zack.struver@keionline.org
+1 (914) 582-1428
FOR RELEASE: MARCH 21, 2016
Non-Profit Groups Urge Obama Administration, NIH to Lower Price of Government-Funded, $129,000 Per Year Prostate Cancer Drug
The groups asked the National Institutes of Health to “take this opportunity to act” to lower the price of the prostate cancer drug Xtandi and show leadership on deterring discriminatory pricing practices.
On 17 March 2016, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) released a 76-page report entitled, Health Product Research & Development Fund: A Proposal for Financing and Operation.
I have provided an update on our work on US government owned patents here:
On Monday, March 7, 2016, from 1:45 P.M. to 2:45 P.M., the US Patent and Trademark Office (USPTO) met with invited stakeholders in a briefing at the White House on the Beijing Treaty on Audiovisual Performances and the implementation package that was sent to Congress on February 29, 2016. The package was submitted for review to the Senate Foreign Relations and Judiciary Committees.
Other KEI comments on NIH licenses can be found here: /nih-licenses
On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.
In early March 2016, the World Trade Organization’s (WTO) TRIPS Council discussed “Intellectual Property and Innovation: Education and Diffusion”. The following delegations co-sponsored discussion of this item on Education and Diffusion – Australia, European Union, Switzerland, United States, Japan, Singapore, Peru, Russian Federation, Chinese Taipei and Hong Kong China.
This is a slightly expanded version of the testimony we provided at the March 1, 2016 USTR Special 301 hearing. I had some trouble uploading to Regulations.Gov, but emailed a copy to Christine R. Peterson, the Director for Intellectual Property and Innovation. One addition was this data:
We sent this brief note to the Army today regarding this federal register note: https://federalregister.gov/a/2016-04494
From: Jamie Love
Date: Sat, Mar 5, 2016
To: Phoebe.E.Lenear@usace.army.mil
Subject: Digital Optical Method patentsI am writing about the notice of intent for an exclusive license to patents on the Digital Optical Method (DOMTM ), United States Patent No. 7,495,767.